Table 2 Stem cell mobilization and apheresis for hematopoietic stem cell collection with MGTA-145 and plerixafor.
Variable | N (%) or median (range) |
|---|---|
Patients undergoing mobilization and apheresisa | |
Day 1 | 25 |
Day 2 | 22 |
Plerixafor dose | |
0.24 mg/kg | 24 (96%) |
0.16 mg/kg | 1 (4%) |
MGTA-145 infusion time | 4 minutes (3–10) |
MGTA-145 intended dose given without interruption | |
Day 1 | 25 (100%) |
Day 2 | 22 (100%) |
Venous access for apheresis | |
Central access | 19 (76%) |
Peripheral access | 6 (24%) |
Apheresis target of 4.5 h | |
Day 1 | 24 (96%) |
Day 2 | 22 (100%) |
Apheresis target of ≥ 3 blood volumes ±10% | |
Day 1 | 22 (88%) |
Day 2 | 20 (91%) |
Volume of blood processed during apheresis | 15.2 L (12–19.8) |
Volume of apheresis product collected | 312 mL (259–352) |
Stem cell collection | |
Total days of mobilization/apheresis needed | |
1 | 3 (12%) |
2 | 22 (88%) |
Total stem cell collection, CD34+ cells × 106/ kg | 5 (1.1–16.2) |
Stem cell collection per day, CD34+ cells ×106/kg | |
Day 1, N = 25 | 3.4 (0.3–16.2) |
Day 2, N = 22 | 1.9 (0.5–4.6) |
Stem cell collection targets | |
≥ 2 × 106 CD34+ cells/kg | 22 (88%) |
≥ 2 × 106 CD34+ cells/kg on day 1 | 17 (68%) |
≥ 4 × 106 CD34+ cells/kg | 17 (68%) |
≥ 6 × 106 CD34+ cells/kg | 10 (40%) |
